Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1613-1618

  Telli, M L ^a   Witteles, R M ^a   Fisher, G A ^a   Srinivas, Sandy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiotoxicity; Congestive heart failure; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IMATINIB; INTERFERON; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOGENIC SHOCK; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC DYSFUNCTION;

EID: 50849094516     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn168     Document Type: Article

References (19)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody agaost HER2 for metastatic breast cancer that overexpresses HER2. [see comment]. N Engl J Med 2001; 344:(11) 783-792.
2. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. [see Geyer CE, comment], N EngI J Med 2006; 355:(26): 2733-2743.
3. Perez EA, Byrne JA, Hammond IW et al. Result of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 2006; 18S (Suppl): 24 Abstr 583.
4. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. [see comment]. Nat Med 2006; 12:(8) 908-916.
5. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110(4): 1233-1237.
6. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7(5): 332-344.
7. Chow LQ, Eckhardt SG, Sunitinib: From rational design to clinical efficacy. J Cin Oncol 2007, 25(7). 884-896.
8. Pfizer. Sutent (Sunitinib) Prescribing Information. 2007 http//www.pfizer.com/pfizer/download/uspi_sutent.pdf (24 September 2007, date last accessed).
9. NIH, Information on Clinical Trials and human Research. US National Inetitute of Health http://www.clinicaltrials.gov (24 September 2007, date last accessed).
10. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alta in metastatic renal-cell carcinoma. N Engl J Med 2007; 3513(2): 115-124.
11. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0,. 2006 http://ctep.cancer.gov (24 September 2007, date last accessed).
12. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007; 25(23): 3525-3533.
13. Slamon DJ, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study, San Antonio, TX, USA 2005 San Antonio Breast Cancer Symposium.
14. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23(31): 7811-7819.
15. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114(23): 2474-2481.
16. Kalay N, Basar E, Ozdogrur I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48(11): 2258-2262.
17. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force. Circulation 2005; 112(112): E154-e235.
18. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10): 685-691.
19. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N EngI J Med 2001; 344(22): 1651-1658.